METHODS FOR TREATING ER+, HER2-, HRG+ BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN ANTI-ERBB3 ANTIBODY

Provided herein are compositions and methods for treating ER+, HER2− HRG+ breast cancer (e.g., metastatic ER+, HER2− breast cancer) in a patient by administering to the patient an anti-ErbB3 antibody (e.g., seribantumab), a CDK4/6 inhibitor (e.g., palbociclib), and an endocrine based therapy (e.g.,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ZHANG, Hong, CZIBERE, Akos, FINN, Gregory J
Format:	Patent
Sprache:	eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Provided herein are compositions and methods for treating ER+, HER2− HRG+ breast cancer (e.g., metastatic ER+, HER2− breast cancer) in a patient by administering to the patient an anti-ErbB3 antibody (e.g., seribantumab), a CDK4/6 inhibitor (e.g., palbociclib), and an endocrine based therapy (e.g., letrozole or fulvestrant) according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule). Also provided herein are compositions and methods for treating ER+, HER2− HRG+ breast cancer (e.g., metastatic ER+, HER2− breast cancer) in a patient by administering to the patient an anti-ErbB3 antibody (e.g., seribantumab) and an endocrine based therapy (e.g., letrozole or fulvestrant) according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule).